Course NURS-6521N-41,Advanced Pharmacology.2018 Winter Qtr 11/26-02/17-PT27 Test Week 9 - Quiz Started 1/27/19 2:26 PM Submitted 1/27/19 3:07 PM Due Date 1/28/19 1:59 AM Status Completed Attempt Score 33 out of 35 points Time Elapsed 40 minutes out of 1 hour and 30 minutes Instructions Please answer each question below and click Submit when you have completed the Quiz. Results Displayed Feedback Question 1 1 out of 1 points An oncology nurse is aware of the risks for injury that exist around the preparation, transportation, and administration of chemotherapeutic agents. In order to reduce these risks of injury, the nurse should take which of the following actions? Response Feedback: IV lines should be primed with a compatible nonhazardous solution before the actual drug administration. Intravenous lines should be disposed of in an approved biohazard container, not normal trash cans. Needleless systems should be used and a toilet is preferable to a commode because it can be flushed of contents without prior handling of waste by care providers. Question 2 1 out of 1 points A 45-year-old woman with acute leukemia is going to begin chemotherapy with vincristine. The nurse is aware that vincristine must always be administered Response Feedback: If vincristine is administered as a continuous infusion, a central line should always be used. It is important to prime IV lines for chemotherapy administration with 5% dextrose in water or normal saline, not with vincristine, before administering the drug. The infusion rate, although important, is not as important a factor for vincristine administration as is the need for a central line. Question 3 1 out of 1 points A patient with a diagnosis of chronic myeloid leukemia has met with her oncologist, who has recommended treatment with the kinase inhibitor imatinib. What route of administration should the nurse explain to the patient?
Response Feedback: Imatinib is administered orally. Consequently, it can be administered in an outpatient environment. IV or IM administration is not performed. Question 4 1 out of 1 points A 28-year-old woman has completed rituximab therapy for an autoimmune disease. She tells the nurse that she and her husband would like to start a family. The nurse will advise her to Response Feedback: Rituximab is not recommended for use in pregnancy or when women are lactating. The patient should consequently be advised to continue using birth control for the duration of treatment. Question 5 1 out of 1 points A patient has been scheduled to begin treatment with rituximab for non-Hodgkin's lymphoma. The nurse who will administer this drug should understand that it targets Response Feedback: Rituximab is a type of monoclonal antibody that binds specifically to the CD20 antigen found on the surface of normal and malignant B lymphocytes and causes cell lysis. The drug does not target the complement system, plasma cell DNA, or the cell membrane of malignant cells.
You've reached the end of your free preview.
Want to read all 10 pages?